# Irinotecan

## Irino IV infusion 100mg/5mL

#### 一般可用

| 藥品代碼       | IIRI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Refractory colorectal malignancies ， 1st line treatment of metastatic colorectal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 用法用量       | Monotherapy (for previously treated patient): [Colorectal cancer， metastatic] 350 mg/m2 as a single agent infused over 90 minutes once every 3 weeks. [Gastric cancer， metastatic or locally advanced] 150 mg/m2 as a single agent infused over 30-90 minutes on days 1 and 15 of a 4-week treatment cycle. Combination therapy (for treatment naive patients):180 mg/m2 over 90 minutes on days 1， 15， and 29 in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin). |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 禁忌           | Known hypersensitivity to irinotecan or any component of the formulation. Coadministraton with azole antifungals (ketoconazole， fluconazole， itraconazole); patients with hereditary fructose intolerance                                                                                                                                                                                                                                                                                                                                                                                             |
| 副作用         | Neutropenia， anemia， thrombocytopenia; acute diarrhoea， sweating， hypersalivation， abdominal cramps， lachrymation， miosis， weakness; nausea， vomiting， alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe， chronic diarrhoea                                                                                                                                                                                                                                                                                              |
| 孕期用藥建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

